Logo image of CREX

CREATIVE REALITIES INC (CREX) Stock Fundamental Analysis

USA - NASDAQ:CREX - US22530J3095 - Common Stock

2.66 USD
0 (0%)
Last: 10/16/2025, 8:00:01 PM
2.641 USD
-0.02 (-0.71%)
After Hours: 10/16/2025, 8:00:01 PM
Fundamental Rating

3

CREX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 95 industry peers in the Media industry. Both the profitability and financial health of CREX have multiple concerns. CREX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

CREX had positive earnings in the past year.
In the past year CREX has reported a negative cash flow from operations.
In multiple years CREX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CREX reported negative operating cash flow in multiple years.
CREX Yearly Net Income VS EBIT VS OCF VS FCFCREX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

The Return On Assets of CREX (-1.94%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -4.19%, CREX is in line with its industry, outperforming 51.58% of the companies in the same industry.
Industry RankSector Rank
ROA -1.94%
ROE -4.19%
ROIC N/A
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
CREX Yearly ROA, ROE, ROICCREX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

CREX's Gross Margin of 43.41% is in line compared to the rest of the industry. CREX outperforms 51.58% of its industry peers.
CREX's Gross Margin has improved in the last couple of years.
CREX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
CREX Yearly Profit, Operating, Gross MarginsCREX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1

2. Health

2.1 Basic Checks

CREX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CREX has more shares outstanding
CREX has more shares outstanding than it did 5 years ago.
CREX has a worse debt/assets ratio than last year.
CREX Yearly Shares OutstandingCREX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CREX Yearly Total Debt VS Total AssetsCREX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CREX has an Altman-Z score of -0.05. This is a bad value and indicates that CREX is not financially healthy and even has some risk of bankruptcy.
CREX's Altman-Z score of -0.05 is on the low side compared to the rest of the industry. CREX is outperformed by 70.53% of its industry peers.
A Debt/Equity ratio of 0.68 indicates that CREX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.68, CREX perfoms like the industry average, outperforming 53.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -0.05
ROIC/WACCN/A
WACC7.06%
CREX Yearly LT Debt VS Equity VS FCFCREX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

CREX has a Current Ratio of 1.01. This is a normal value and indicates that CREX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.01, CREX is in line with its industry, outperforming 41.05% of the companies in the same industry.
A Quick Ratio of 0.93 indicates that CREX may have some problems paying its short term obligations.
CREX's Quick ratio of 0.93 is on the low side compared to the rest of the industry. CREX is outperformed by 63.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.93
CREX Yearly Current Assets VS Current LiabilitesCREX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

5

3. Growth

3.1 Past

CREX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 488.89%, which is quite impressive.
Looking at the last year, CREX shows a decrease in Revenue. The Revenue has decreased by -6.24% in the last year.
Measured over the past years, CREX shows a quite strong growth in Revenue. The Revenue has been growing by 9.98% on average per year.
EPS 1Y (TTM)488.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
Revenue 1Y (TTM)-6.24%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-0.65%

3.2 Future

Based on estimates for the next years, CREX will show a very strong growth in Earnings Per Share. The EPS will grow by 50.60% on average per year.
CREX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.12% yearly.
EPS Next Y137.09%
EPS Next 2Y50.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.11%
Revenue Next 2Y11.12%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CREX Yearly Revenue VS EstimatesCREX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CREX Yearly EPS VS EstimatesCREX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 7.60, the valuation of CREX can be described as very cheap.
Based on the Price/Earnings ratio, CREX is valued cheaper than 84.21% of the companies in the same industry.
When comparing the Price/Earnings ratio of CREX to the average of the S&P500 Index (27.31), we can say CREX is valued rather cheaply.
CREX is valuated quite expensively with a Price/Forward Earnings ratio of 30.09.
CREX's Price/Forward Earnings ratio is in line with the industry average.
CREX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.85.
Industry RankSector Rank
PE 7.6
Fwd PE 30.09
CREX Price Earnings VS Forward Price EarningsCREX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CREX is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.22
CREX Per share dataCREX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CREX's earnings are expected to grow with 50.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y50.6%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CREX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CREATIVE REALITIES INC

NASDAQ:CREX (10/16/2025, 8:00:01 PM)

After market: 2.641 -0.02 (-0.71%)

2.66

0 (0%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners14.87%
Inst Owner Change0%
Ins Owners16.83%
Ins Owner Change22.55%
Market Cap27.98M
Analysts84
Price Target6.76 (154.14%)
Short Float %2.21%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)225.73%
Min EPS beat(2)-149.99%
Max EPS beat(2)601.45%
EPS beat(4)2
Avg EPS beat(4)117.54%
Min EPS beat(4)-149.99%
Max EPS beat(4)601.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.64%
Min Revenue beat(2)-11.52%
Max Revenue beat(2)6.23%
Revenue beat(4)3
Avg Revenue beat(4)0.2%
Min Revenue beat(4)-11.52%
Max Revenue beat(4)6.23%
Revenue beat(8)4
Avg Revenue beat(8)-1.96%
Revenue beat(12)4
Avg Revenue beat(12)-3.57%
Revenue beat(16)4
Avg Revenue beat(16)-3.18%
PT rev (1m)0%
PT rev (3m)20.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-189.48%
EPS NY rev (1m)-17.24%
EPS NY rev (3m)-54.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.74%
Valuation
Industry RankSector Rank
PE 7.6
Fwd PE 30.09
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB N/A
EV/EBITDA 15.22
EPS(TTM)0.35
EY13.16%
EPS(NY)0.09
Fwd EY3.32%
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS4.58
BVpS2.8
TBVpS-1.78
PEG (NY)0.06
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.94%
ROE -4.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.41%
FCFM N/A
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
F-Score3
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA 6.52
Cap/Depr 54.53%
Cap/Sales 5.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 0.93
Altman-Z -0.05
F-Score3
WACC7.06%
ROIC/WACCN/A
Cap/Depr(3y)115.1%
Cap/Depr(5y)95.1%
Cap/Sales(3y)8.11%
Cap/Sales(5y)6.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)488.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
EPS Next Y137.09%
EPS Next 2Y50.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.24%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-0.65%
Revenue Next Year4.11%
Revenue Next 2Y11.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-161.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year580.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-268.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.91%
OCF growth 3Y93.04%
OCF growth 5YN/A